VBWG
Data alert

A substudy of MIRACL (Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering): Effects of intensive statin therapy on stroke in patients with acute coronary syndrome

Stroke ranks third as a cause of death in the United States and is a leading cause of serious long-term disability.1 Although stroke mortality rates have declined, the number of stroke deaths actually rose in the 1990s, because the rate of decline has slowed and the number of elderly people has increased substantially. Given that stroke is more common in the elderly, this trend may continue as the percentage of older individuals grows. Additionally, obesity is epidemic in the United States and is a major risk factor for stroke. These prospects underscore the importance of intensifying stroke prevention efforts.

References are listed at the end of the Data Alert.





DA12.ppt

Download DA12.ppt (5 slides - 0.6MB)

Slide 1 Slide 2 Slide 3 Slide 4 Slide 5
Data_Alert.pdf (0.3MB)Data_Alert.pdf (0.3MB)


A substudycholesterolcoronarydisabilityIschemiaMIRACLMyocardialranksseriousStatesstatinStroke

Related at vwbg.org

MIRACL: Very early statin therapy not guided by cholesterol levels is beneficial in acute coronary syndromes

Final results of the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) trial have been published and confirm that treatment with atorvastatin 80 mg/d early during an acute coronary syndrome (ACS) reduces the risk of early recurrent events, primarily recurrent symptomatic ischemia during hospitalization.

Core Curriculum

Myocardial Ischemia Redefined: Optimal Care in CAD

View/Download individual slides (90 Slides)
More related